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Abstract: G protein-coupled receptor 68 (GPR68) is a proton sensor that is activated upon binding to extracellular 
protons. We have previously found that GPR68 induces a proapoptotic pathway in bone marrow (BM) cells from the 
patients with myelodysplastic syndromes (MDS) after treated with lenalidomide. However, the function of GPR68 in 
normal hematopoietic cells remains unclear. With genetic loss of function approach, we found reduced frequency 
and number of B lymphocytes in the peripheral blood (PB) of whole body Gpr68-/- mice compared to control litter-
mates upon aging. During hematopoietic regeneration, such as in response to fluorouracil (5-FU), we also found 
reduced frequency and number of B lymphocytes in Gpr68-/- mice compared to wild type mice. Mechanism studies 
revealed that Gpr68 expression was upregulated in B lymphocytes of BM during aging and in hematopoietic progeni-
tor cells after treatment with 5-FU. In addition, activation of Gpr68 by its activators increased the frequency and 
number of B lymphocytes. Our studies indicate that Gpr68 expression is upregulated in hematopoietic cells upon 
aging and during hematopoietic regeneration that ends up with increased number of B lymphocytes. 
Keywords: G protein-coupled receptors, GPR68 agonist, GPR68 allosteric modulator, hematopoiesis, stress hema-
topoiesis, hematologic regeneration
Introduction
The bone marrow (BM) microenvironment has 
long been known to have low oxygen levels [1]. 
Local acidosis is frequently observed in areas 
of ischemia or hypoxia [2]. This prompts us to 
ask whether local acidosis regulates hemato-
poiesis and the molecular mechanism involved. 
The G protein-coupled receptor 68 (GPR68), 
also known as ovarian cancer G protein-cou-
pled receptor 1 (OGR1), responds to extracel-
lular acidosis, i.e. protons [3]. Upon activation, 
GPR68 couples to G protein q/11 (Gq/11), 
leading to activation of the phospholipase 
C/calcium (Ca2+) pathway [3, 4]. In addition, 
GPR68 can also couple to G protein s (Gs), lead-
ing to activation of the adenylyl cyclase/cAMP 
pathway [5]. GPR68 is implicated in pleotropic 
pathophysiological processes, such as cancer, 
inflammation, bone absorption and steer stress 
response [6-9]. We have recently demonstrated 
that GPR68 expression is induced by lenalido-
mide [4], an immunomodulatory drug used for 
patients with myelodysplastic syndromes (MDS) 
and multiple myeloma [10, 11]. Upregulation 
of GPR68 mediates a calcium/calpain proapop-
totic pathway in MDS cells [4]. Despite GPR68’s 
various pathophysiological functions, genetic 
deletion of Gpr68 in mice (i.e. whole body 
Gpr68-/- mice) results in only a mild phenotype 
[12]. In particular, the Gpr68-/- mice display very 
marginal phenotypes in hematopoietic tissues, 
indicating a dispensable role of Gpr68 in hema-
topoiesis under steady state conditions. How- 
ever, the potential roles of Gpr68 during aging 
and/or under stressed conditions are essen-
tially unknown. In the present study, we exam-
ined the hematopoietic phenotype of Gpr68-/- 
mice during aging and under stressed condi-
tions, i.e. during hematopoietic regeneration. 
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Materials and methods
Mice 
Gpr68 knockout (KO, i.e. Gpr68-/-) mice (on a 
C57Bl/6 background) [12, 13] and wild type 
(WT) mice (on a C57Bl/6 background) were 
bred, housed and handled in the Association 
for Assessment and Accreditation of Laboratory 
Animal Care-accredited animal facility of Uni- 
versity of South Carolina. Peripheral blood (PB) 
cells were collected from retro-orbital veins and 
measured with the VetScan HM5 (Abaxis). Bone 
marrow (BM) cells were harvested from tibia, 
femur and pelvic bones, and maintained in 
IMDM with 2% fetal bovine serum and 100 U/
mL penicillin and streptomycin. 
Injection 
To study hematopoiesis under stress, a single 
dose of fluorouracil (5-FU, 50 mg/kg) was 
injected intraperitoneally into WT and Gpr68 
KO mice [14]. To examine the effect of Gpr68 
activators on hematopoiesis, Ogerin (10 mg/kg 
in saline) or 3,5-disubstituted isoxazole (Isx, 16 
mg/kg in 20% w/v 2-hydroxypropyl-β-cyclodex- 
trin) were injected intraperitoneally to WT mice 
for five consecutive days [15, 16]. 
Cell culture
Lineage negative (Lin-) BM cells were enriched 
with EasySepTM Mouse Hematopoietic Pro- 
genitor Cell Enrichment Kit (StemCell Tech- 
nologies, 19756) according to the manufac-
ture’s recommendation. Antibodies labeling lin-
eage positive cells include CD3, B220, CD11b, 
Gr1 and Ter119. Lin- cells were cultured in 
RPMI1640 media, supplemented with 10% 
FBS and 100 U/mL penicillin/streptomycin, 10 
ng/mL mouse stem cell factor (Peprotech, 250-
03), 10 ng/mL mouse interleukin 3 (Peprotech, 
213-13), and 10 ng/mL human interleukin 6 
(Peprotech, 200-06). Lin- cells were treated 
with 5-FU (10 μM) for 24 hours, followed by 
examination of Gpr68 mRNA. 
Flow cytometry
For immunophenotypic analysis of lymphoid 
and myeloid cells, 20 μL PB samples were 
treated with 1 mL 1× red blood cell (RBC) lysis 
buffer (BD Biosciences, 555899) at 37° for 30 
minutes. The cells were washed and incubated 
with antibodies, including CD11b (eBioscience, 
15-0112-83), Gr1 (eBioscience, 48-5931-82), 
CD3 (eBioscience, 12-0031-83), B220 (eBio-
science, 17-0452-81), at 4° for 30 minutes. 
The cells were then washed again before analy-
sis with flow cytometer. Alternatively, BM cells 
and splenocytes were stained with CD3, B220, 
CD11b, Gr1 and Ter119 (eBioscience, 25-5921-
82). To analyze Gpr68 expression, PB cells and 
BM cells were incubated with Gpr68 antibody 
(Alomone Labs, AGR-042), followed by staining 
with secondary antibody (Jackson Immuno- 
Research, 111-096-144). Analysis was per-
formed using NovoCyte Flow Cytometer with 
NovoExpress software. 
Quantitative RT-PCR
Total RNA was extracted and purified using 
Quick-RNA MiniPrep (Zymo research, R1055) 
and reverse transcription was carried out using 
SuperScript VILO cDNA Synthesis Kit (In- 
vitrogen). Quantitative PCR was performed wi- 
th Taqman Master Mix (Life Technologies) for 
mGapdh (Cat 4331182, Assay ID Mm999- 
99915_g1, Applied Biosystems) and mGpr68 
(Cat 4331182, Assay ID Mm00558545_s1, 
Applied Biosystems).
Statistical analysis
Results are shown the mean ± s.e.m. Student’s 
t-test was used for all the results with GraphPad 
Prism (v7, GraphPad).
Results
Deletion of Gpr68 reduces the number of B 
lymphocytes in older mice
Previous studies have shown that whole body 
Gpr68 knockout (KO, Gpr68-/-) mice on a mixed 
genetic background exhibit similar hematopoi-
etic output as compared to the wild type (WT, 
Gpr68+/+) mice [12]. To address the potential 
influence from genetic background, we charac-
terized the hematopoietic phenotype of whole 
body Gpr68 KO mice on a congenic genetic 
background (i.e. C57Bl/6). Successful deletion 
of Gpr68 and reduced Gpr68 expression was 
confirmed by genotyping and quantitative 
RT-PCR (Figure S1A, S1B). Complete blood 
count (CBC) revealed comparable levels of 
white blood cells (WBC) in peripheral blood (PB) 
from Gpr68 KO and WT mice at either younger 
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(2-month old) or older age (12-month old, 
Figure 1A). Analysis of cell surface immunophe-
notype revealed reduced frequencies of B220+ 
B lymphocytes but increased frequencies of 
CD11b+ myeloid cells (including neutrophils 
and monocytes) in PB from Gpr68 KO mice 
than those from WT mice at older age (12-
month old, Figure 1B, 1C). Particularly, the 
number of B lymphocytes largely reduced in PB 
from Gpr68 KO mice than those from WT mice 
at older age (12-month old, Figure 1D). Con- 
sistently, the frequencies of B lymphocytes 
were also reduced in bone marrow (BM) and 
spleens of Gpr68 KO mice compared with WT 
mice at 12-month of age (Figure 1E). In con-
trast, the number of myeloid cells only slightly 
increased in PB from Gpr68 KO mice than 
those from WT mice at older age (12-month old, 
Figure 1D). The levels of CD3+ T lymphocytes, 
red blood cells (RBC), hemoglobin or platelets 
were comparable in PB from WT and Gpr68 KO 
mice (Figures 1B-D, S1C-E). These data sug-
gest that Gpr68 increases the number of B lym-
phocytes in PB during aging. 
Deletion of Gpr68 reduces the number of B 
lymphocytes in response to 5-FU
Fluorouracil (5-FU), a chemotherapeutic agent, 
mediates cytotoxicity of hematopoietic progeni-
tor cells, and has been commonly used to study 
hematopoietic regeneration after stress [14]. 
To explore a potential function of Gpr68 during 
hematopoietic regeneration, a single dose of 
5-FU (50 mg/kg) was injected into WT or Gpr68 
KO mice. As expected, 5-FU reduced the num-
ber of WBC, followed by recovery of WBC count 
a week after 5-FU injection, indicating hemato-
Figure 1. Deletion of Gpr68 reduces the number of B lymphocytes. A. Number of WBC in PB from WT and Gpr68 KO 
mice at 2-month old (2 m) and 12-month old (12 m) (n=4~9). B. Frequencies of CD3+ T cells (left), B220+ B cells 
(middle) and CD11b+ myeloid cells (right) in PB from WT and Gpr68 KO mice at 2-month old (2 m) and 12-month 
old (12 m) (n=4~5). C. Representative flow cytometric analysis of CD3+ T cells, B220+ B cells and CD11b+ myeloid 
cells in PB from WT and Gpr68 KO mice at 12-month old. D. Number of CD3+ T cells (left), B220+ B cells (middle) 
and CD11b+ myeloid cells (right) in PB from WT and Gpr68 KO mice at 2-month old (2 m) and 12-month old (12 m) 
(n=4~5). E. Frequencies of B220+ B cells in BM and spleens from WT and Gpr68 KO mice at 12-month old (n=3~5).
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poietic regeneration (Figure 2A). Compared to 
WT mice, Gpr68 KO mice had a slower regen-
eration rate as evidenced by lower numbers of 
WBC at day 3 and day 10 post 5-FU injection 
(Figure 2A). We also examined the frequencies 
of the lymphoid and myeloid lineages in WT and 
Gpr68 KO mice after 5-FU injection. At day 7 
post 5-FU injection, the frequencies of B lym-
phocytes were lower, while the frequencies of 
myeloid cells were higher in PB from Gpr68 KO 
mice compared to those from WT mice (Figure 
1B, 1C). In particular, the number of B cells was 
reduced in PB from Gpr68 KO than those from 
WT mice day 10 post 5-FU injection (Figure 2D). 
The levels of T lymphocytes, RBC, hemoglobin 
or platelets were comparable in PB from WT 
and Gpr68 KO mice after 5-FU injection (Figures 
2B-D, S2A-C). Our findings suggest that Gpr68 
increases the number of B cells in PB during 
hematopoietic regeneration.
Gpr68 expression is upregulated in older mice 
and in response to 5-FU
It has been demonstrated that overexpression 
of G protein-coupled receptors increases their 
basal level of activation [17]. This prompts us to 
examine the expression of Gpr68 in hematopoi-
etic cells during aging and upon stress. Previous 
studies revealed that Gpr68 mRNA was detect-
able in PB cells [12]. As expected, Gpr68 pro-
Figure 2. The effect of 5-FU on PB cells from WT and Gpr68 KO mice. A. Number of WBC in PB from WT and Gpr68 
KO mice after 5-FU injection at the indicated time points (n=5). B. Frequencies of CD3+ T cells (left), B220+ B cells 
(middle) and CD11b+ myeloid cells (right) in PB from WT and Gpr68 KO mice after 5-FU injection at the indicated 
time points (n=5). C. Representative flow cytometric analysis of CD3+ T cells, B220+ B cells and CD11b+ myeloid 
cells in PB from WT and Gpr68 KO mice at day 7 post 5-FU injection. D. Number of CD3+ T cells (left), B220+ B cells 
(middle) and CD11b+ myeloid cells (right) in PB from WT and Gpr68 KO mice after 5-FU injection at the indicated 
time points (n=5). #, P<0.1; *, P<0.05. 
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tein was expressed at higher levels in PB cells 
(mean fluorescence intensity ~105), including T 
lymphocytes, B lymphocytes and myeloid cells 
(Figure 3A, 3B). In contrast, Gpr68 protein was 
expressed at much lower levels in BM hemato-
poietic cells (mean fluorescence intensity 
~104), including T lymphocytes, B lymphocytes, 
myeloid cells and Ter119+ erythroid cells 
(Figure 3C). Notably, Gpr68 expression was 
upregulated in B lymphocytes and myeloid cells 
in BM of older mice (20-month old) than young-
er mice (5-month old) (Figure 3C). In addition, 
Gpr68 mRNA was also upregulated in BM lin-
eage negative (Lin-) hematopoietic progenitor 
cells after treated with 5-FU (Figure S2D). 
These data suggest that aging and regenera-
tion are two conditions to induce Gpr68 expres-
sion, indicating increased level of Gpr68 
activation.
Activation of Gpr68 increases the number of B 
lymphocytes
To determine whether GPR68 was functionally 
involved, we used two GPR68 modulators that 
have been shown to activate GPR68 function. 
Figure 3. The effect of Gpr68 activators on hematopoietic output. (A) Representative flow cytometric analysis of 
Gpr68 expression in PB cells from WT mice. (B, C) Gpr68 protein expression in PB cells (B) and BM cells (C) from 
WT mice at 5-month old (5 m) and 20-month old (20 m) (n=4). (D) Number of WBC in PB from WT mice after injec-
tion with Ogerin (red) or Isx (blue) at the indicated time points (n=5). (E) Frequencies of CD3+ T cells (left), B220+ B 
cells (middle) and CD11b+ myeloid cells (right) in PB from WT mice after injection with Ogerin (red) or Isx (blue) at 
the indicated time points (n=5). (F) Number of CD3+ T cells (left), B220+ B cells (middle) and CD11b+ myeloid cells 
(right) in PB from WT mice after injection with Ogerin (red) or Isx (blue) at the indicated time points (n=5). *, P<0.05.
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Ogerin is demonstrated as a positive allosteric 
modulator for GPR68, activating either the 
cAMP or the Ca2+ pathway in the presence of 
extracellular protons [9, 16]. 3,5-disubstituted 
isoxazole (Isx) acts as an agonist of GPR68 that 
activates the Ca2+ pathway irrespective of pH 
[15]. To examine the effects of Ogerin and Isx 
on hematopoiesis, we injected Ogerin (5 mg/kg 
daily) or Isx (16 mg/kg daily) into WT mice for 5 
consecutive days. We found increased number 
of WBC in PB from WT mice after Ogerin injec-
tion (Figure 3D). In contrast, the number of 
WBC was unaltered in PB from WT mice treated 
with Isx (Figure 3D). The frequencies of B lym-
phocytes were increased, while the frequencies 
of T lymphocytes and myeloid cells were 
reduced in PB from WT mice after Ogerin injec-
tion (Figure 3E). Isx injection induced similar 
effects (Figure 3E). Accordingly, the number of 
B lymphocytes was increased in PB of WT mice 
after injection with Ogerin or Isx (Figure 3F). 
Injection with Isx but not Ogerin reduced the 
number of T cells (Figure 3F). Both Ogerin and 
Isx injection reduced the number of myeloid 
cells (Figure 3F). Consistent with Gpr68 overex-
pression data, our studies indicate that Gpr68 
activation increases the number of B lympho-
cytes, possibly through the Ca2+ pathway. 
Discussion 
The bone marrow microenvironment has long 
been known as hypoxic that leads to local aci-
dosis [1, 2]. Whether local acidosis will regulate 
hematopoiesis is unclear. Given that GPR68 
responds to extracellular protons [3], we exam-
ined whether GPR68 regulates hematopoiesis 
with a genetic loss of function approach. Under 
a mixed genetic background, deletion of Gpr68 
resulted in a slight increase in the number of 
neutrophils under steady state [12]. Consis- 
tently, we found that deletion of Gpr68 under a 
pure genetic background also resulted in a 
slight increase in the number of myeloid cells in 
PB of older mice. More importantly, the number 
of B lymphocytes were significantly reduced in 
PB, BM and spleens from older Gpr68 KO mice 
compared to the age matched WT mice, indi-
cating reduced development of B lymphocytes 
upon aging due to deletion of Gpr68. In addi-
tion, when we used 5-FU to stress hematopoi-
etic cells, we also found reduced number of B 
lymphocytes in PB from Gpr68 KO mice com-
pared to WT mice. These data suggest that 
Gpr68 increases the number of B lymphocytes 
under stressed conditions, such as aging and 
hematopoietic regeneration.
Intriguingly, we found increased Gpr68 expres-
sion in B lymphocytes and myeloid cells in BM 
from older WT mice compared to younger WT 
mice. We also found increased Gpr68 tran-
script in BM hematopoietic progenitor cells in 
response to 5-FU treatment. Given that overex-
pression of GPR68 will increase its activity [4, 
17], our data suggest that activation of Gpr68 
promotes the development of B cells at the 
expense of myeloid cells. To further validate 
this observation, we treated WT mice with two 
Gpr68 modulators, Ogerin and Isx, that acti-
vates Gpr68 function. Consistent with Gpr68 
overexpression, activation of Gpr68 in vivo 
increases the number of B lymphocytes in PB. 
Given that both Ogerin and Isx activates Grp68-
mediated Ca2+ pathway, our data suggest that 
Gpr68 favors lymphopoiesis towards B cell lin-
eage through activating a Ca2+ pathway. How- 
ever, the downstream signaling events need 
further study. 
Our studies suggest that local acidosis of the 
BM microenvironment could impact on hemato-
poiesis, partly through a proton sensor Gpr68. 
Overexpression or activation of Gpr68 increas-
es the number of B lymphocytes, possibly 
through activating the Ca2+ pathway. The Gpr68 
modulators are useful tools to understand the 
pathophysiological function of GPR68 in vivo. 
However, the cell and molecular mechanism of 
how Gpr68 regulates B cell development and 
whether Gpr68 regulates B cell function needs 
further study.
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Figure S1. Loss of Gpr68 did not affect 
RBC or platelets. (A) Representative 
genotype of Gpr68 KO mice. (B) Gpr68 
transcript expression in BM cells from 
WT and Gpr68 KO mice. (C-E) Levels of 
RBC (C), hemoglobin (D) and platelets 
(E) in PB from WT and Gpr68 KO mice 
at 2-month old (2 m) and 12-month old 
(12 m) (n=4~9).
Figure S2. The effect of 5-FU on PB cells from WT and Gpr68 KO mice. (A-C) Levels of RBC (A), hemoglobin (B) and 
platelets (C) in PB from WT and Gpr68 KO mice after 5-FU injection at the indicated time points (n=5). (D) Gpr68 
transcript expression in Lin- BM cells after treatment with 5-FU (n=4).
